Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | Egrifta SV, Egrifta WR, tesamorelin acetate, GHRF analog |
| Category | Growth Hormone Secretagogues |
| Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular weight | 5135.86 Da |
| Half-life | ~26–38 min (SC) |
| Mechanism (summary) | Tesamorelin is a synthetic growth hormone-releasing factor analog, FDA-approved as Egrifta SV and Egrifta WR formulations for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The two formulations are explicitly not substitutable. It is not a general weight-loss drug. |
| Dosing notes | Dosing is formulation-specific and not substitutable: Egrifta SV is 1.4 mg subcutaneously once daily, Egrifta WR is 1.28 mg subcutaneously once daily. |
| Storage |
Per FDA label: Egrifta WR is stored at room temperature; the reconstituted vial may be used for 7 consecutive daily doses before discard. Egrifta SV is reconstituted immediately before use and discarded if not used immediately — the reconstituted solution is neither refrigerated nor frozen. |
| Read more | Full reference → |
|---|